Bioventus has completed its acquisition of CartiHeal.
CartiHeal is an alternative for the approximately 650,000 U.S. patients who receive microfracture or debridement annually, and can potentially delay the need for a total knee replacement in patients with joint surface lesions. The acquisition of CartiHeal is aligned with Bioventus’ sports medicine and total joint reconstruction call point. In a randomized controlled clinical trial, CartiHeal’s Agili-C™ implant demonstrated superiority to either microfracture or debridement.
In March, CartiHeal received FDA Premarket Approval of its Agili-C implant. Agili-C was granted Breakthrough Device Designation by FDA in 2020, and is indicated for the treatment of International Cartilage Repair Society grade III or above knee joint surface lesions, with a total treatable area of 1-7 cm2 for patients without severe osteoarthritis.
The company will provide adjusted earnings per share guidance reflecting the acquisition on its upcoming 2Q22 earnings call.
Ken Reali, Bioventus’ Chief Executive Officer, said, “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant medium- and long-term potential as evidenced by the robust data generated from its pivotal clinical trial showing superiority to current treatments. We believe that the addition of CartiHeal will complement our joint preservation technologies and specifically our HA business, further supporting our short- and mid-term growth drivers and helping us to deliver on our goal of sustained double-digit revenue growth.”
Bioventus has completed its acquisition of CartiHeal.
CartiHeal is an alternative for the approximately 650,000 U.S. patients who receive microfracture or debridement annually, and can potentially delay the need for a total knee replacement in patients with joint surface lesions. The acquisition of CartiHeal is aligned with Bioventus’ sports...
Bioventus has completed its acquisition of CartiHeal.
CartiHeal is an alternative for the approximately 650,000 U.S. patients who receive microfracture or debridement annually, and can potentially delay the need for a total knee replacement in patients with joint surface lesions. The acquisition of CartiHeal is aligned with Bioventus’ sports medicine and total joint reconstruction call point. In a randomized controlled clinical trial, CartiHeal’s Agili-C™ implant demonstrated superiority to either microfracture or debridement.
In March, CartiHeal received FDA Premarket Approval of its Agili-C implant. Agili-C was granted Breakthrough Device Designation by FDA in 2020, and is indicated for the treatment of International Cartilage Repair Society grade III or above knee joint surface lesions, with a total treatable area of 1-7 cm2 for patients without severe osteoarthritis.
The company will provide adjusted earnings per share guidance reflecting the acquisition on its upcoming 2Q22 earnings call.
Ken Reali, Bioventus’ Chief Executive Officer, said, “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant medium- and long-term potential as evidenced by the robust data generated from its pivotal clinical trial showing superiority to current treatments. We believe that the addition of CartiHeal will complement our joint preservation technologies and specifically our HA business, further supporting our short- and mid-term growth drivers and helping us to deliver on our goal of sustained double-digit revenue growth.”
Copy to clipboard 
